---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-26-000003"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:23:53.952389+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LENZ Q4 2025 prelim product rev $1.6M; >20K prescriptions for VIZZ launch

## Summary
- Net product revenue of ~$1.6M from VIZZ in first launch quarter (Q4 2025), with over 20,000 prescriptions filled.
- Over 6,500 unique eye care professionals prescribed VIZZ; more than 55% prescribed multiple times in Q4.
- VIZZ launched October 2025; broad retail and epharmacy access achieved by mid-November 2025.
- Announced fourth international commercialization partnership with Lunatus for Middle East with milestones and revenue share.

## SEC filing metadata
- accession: 0001815776-26-000003
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/0001815776-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/lenz-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-26-000003
- JSON: https://secwatch.observer/filing/0001815776-26-000003.json
- Plain text: https://secwatch.observer/filing/0001815776-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.